{"id":"NCT03785145","sponsor":"Medy-Tox","briefTitle":"MT10109L in the Treatment of Lateral Canthal Lines","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-20","primaryCompletion":"2020-02-27","completion":"2021-01-25","firstPosted":"2018-12-24","resultsPosted":"2023-10-05","lastUpdate":"2023-10-05"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthal Lines"],"interventions":[{"type":"DRUG","name":"MT10109L","otherNames":["NivobotulinumtoxinA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MT10109L","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.","primaryOutcome":{"measure":"The Percentage of Participants With a â‰¥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of Lateral Canthal Lines (LCL) Severity at Maximum Smile at Day 30","timeFrame":"Day 30","effectByArm":[{"arm":"Placebo","deltaMin":2,"sd":null},{"arm":"MT10109L","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":12},"locations":{"siteCount":14,"countries":["United States","Russia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":76},"commonTop":[]}}